Shares plunged 11% to $11.21 as Telix Pharmaceuticals unveiled its largest-ever deal: a US$1.65 billion acquisition of Germany's ITM Isotope Technologies Munich, a privately held company that makes the radioactive materials used in a fast-growing class of cancer treatments. The market's verdict was swift and skeptical — and the reasons are worth unpacking.
• Existing Shareholders Are Getting Diluted by Nearly a Quarter. Telix will pay $1.65 billion upfront, with roughly $1.25 billion paid in Telix shares priced at $11.84 apiece, plus the assumption of $302 million of ITM debt. The 105.8 million new shares being issued swell Telix's share count from approximately 339 million outstanding to about 445 million — a roughly 31% increase. That means every existing shareholder's slice of future earnings just got meaningfully smaller. There's also up to $700 million more in potential payments if ITM's lead drug wins approval and hits sales targets , so the total bill could reach $2.35 billion.
• The Crown Jewel Drug Just Got Rejected by the FDA. On August 7, the FDA declined to approve ITM-11, ITM's lead cancer therapy for a rare group of gastrointestinal tumors.
The rejection letter cited manufacturing issues, not concerns about the drug's effectiveness or safety. The clinical data was strong — patients receiving the drug went 23.9 months without their cancer progressing, versus 14.1 months on an existing treatment — but investors are now being asked to fund an asset whose path to market is uncertain and whose manufacturing problems Telix must fix.
• The Strategic Logic: Control the Supply Chain, Challenge Novartis. ITM is the world's leading supplier of therapeutic radioisotopes, including lutetium-177 , the key ingredient in Novartis's blockbuster prostate cancer drug Pluvicto.
Telix says the merger will make it a vertically integrated company — meaning it would control everything from raw materials to finished drugs. That's a real competitive advantage in a field where isotope supply is scarce.
• Telix's Finances Can Absorb the Deal — Barely. First-half 2026 revenue hit $477 million, up 22% year-over-year , and profit after tax was $38 million. But the company carries $467 million in debt against $142 million in cash , and it's now layering on $302 million more from ITM. The balance sheet will be stretched thin while Telix works to clear ITM-11's manufacturing hurdles and integrate a 485-person foreign operation.
The deal's logic is sound on paper — own your supply chain, build a pipeline — but the price tag is steep and the FDA setback adds real execution risk. Shareholders are right to ask: is this a transformational leap or an expensive gamble?